Cisplatin, mitomycin, and interferon-alpha 2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma

Metintas, MUZAFFER; Ozdemir, N; Ucgun, I; Elbek, O; Kolsuz, M; Mutlu, S; Metintas, SELMA

doi:10.1378/chest.116.2.391

Cisplatin, mitomycin, and interferon-alpha 2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma

Metintas M., Ozdemir N., Ucgun I., Elbek O., Kolsuz M., Mutlu S., ...Daha Fazla

CHEST, cilt.116, sa.2, ss.391-398, 1999 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 116 Sayı: 2
Basım Tarihi: 1999
Doi Numarası: 10.1378/chest.116.2.391
Dergi Adı: CHEST
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.391-398
Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Study objective: To investigate the therapeutic activity and toxicity of combination chemoimmunotherapy with cisplatin, mitomycin, and interferon (IFN)-alpha 2a, by comparing the responses in a group of patients with diffuse malignant pleural mesothelioma (DMPM) to the responses in a control group of DMPM patients given supportive care alone.